Signum Dermalogix, Inc. entered into an agreement with Dermata Therapeutics to develop a topical product for the treatment of patients with rosacea. SIG990 is a novel, first-in-class anti-inflammatory compound, which has the potential to both reduce erythema and decrease the papules and pustules associated with the disease. The Investigational New Drug (IND) application for SIG990 has been cleared by the FDA and SIG990 is ready to be evaluated in subjects. Dermata has obtained an exclusive worldwide license to SIG990 and is responsible for the clinical development of the product. Dermalogix will receive milestone payments and royalties on revenues of the product.

Several drugs to treat rosacea that currently on the market or in development treat either erythema or inflammatory lesions associated with rosacea, but not both. A safe, topical treatment that addresses both symptoms would be a significant therapeutic option for rosacea patients.

Maxwell Stock, CEO of Signum Dermalogix, Inc., commented, "We are excited to partner with Dermata and look forward to working with their experienced team to advance SIG990 in the clinic. Partnering allows us to share expertise and thereby provides an effective way of progressing cutting edge research and development. I'd also like to thank the National Institute of Allergy and Infectious Diseases (NIAID) for their support in helping fund this drug development program."

According to David Hale, acting CEO of Dermata, "We believe that this first-in-class compound SIG990 has the potential to be a significant treatment option for patients with rosacea. This disease, while not life-threatening, can have a serious impact on the quality of life of patients. We are excited about moving SIG990 into patients in a Phase II clinical trial."